Relationship between adherence level to statins, clinical issues and health-care costs in real-life clinical setting

Value in Health

Volumn 13, Issue 1, 2010, Pages 87-94

  Dragomir, Alice ^a   Côté, Robert ^b   White, Michel ^a   Lalonde, Lyne ^a   Blais, Lucie ^a   Bérard, Anick ^a   Perreault, Sylvie ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Adherence to treatment; Health care costs; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CANADA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH SERVICE; HEART FAILURE; HOSPITALIZATION COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

EID: 72949105588     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2009.00583.x     Document Type: Article

References (51)

1. Fondation des maladies du Coeur du Canada. (Fondation des maladies du Coeur du Canada). Le fardeau croissant des maladies cardiovasculaires et des accidents vasculaires cérébraux au Canada, 2003. Report No.: 1-89624-32-4.
2. Thom T, Haase N, Rosamond W, et al. Heart Disease and Stroke Statistics - 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006 113 : e85 151.
3. Mark DB, Van de Werf FJ, Simes RJ, et al. Cardiovascular disease on a global scale: defining the path forward for research and practice. Eur Heart J 2007 28 : 2678 2684.
4. Goldstein LB, Adams R, Alberts MJ, et al. Stroke 2006 37: 1583 1633.
5. Lloyd-Jones DM, Wilson PW, Larson MG, et al. Lifetime risk of coronary heart disease by cholesterol levels at selected ages. Arch Intern Med 2003 163 : 1966 1972.
6. Genest J, Frohlich J, Fodor G, McPherson R. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: 2006 update. CMAJ 2006 169 : 921 924.
7. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. NEJM 1995 333 : 1301 1307.
8. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998 279 : 1615 1622.
9. Sever PS, Poulter NR, Dahlöf B, Wedel H. Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOTT-LLA). Am J Cardiol 2005 96 : 39F 44.
10. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 2003 361 : 2005 2016.
11. Briel M, Studer M, Glass TR, Bucher HC. Effects of statins on stroke prevention in patients with and without coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med 2004 117 : 596 606.
12. Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Intern Med 2006 166 : 2307 2313.
13. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003 326 : 1423.
14. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002 288 : 462 467.
15. Perreault S, Blais L, Lamarre D, et al. Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention. Br J Clin Pharmacol 2005 59 : 564 573.
16. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002 288 : 455 461.
17. Perreault S, Blais L, Dragomir A, et al. Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease. Eur J Clin Pharmacol 2005 61 : 667 674.
18. Krousel-Wood M, Thomas S, Muntner P, Morisky D. Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin Cardiol 2004 19 : 357 362.
19. Ho PM, Magid DJ, Shetterly SM, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J 2008 155 : 772 779.
20. Statistics Canada Health Division. Canadian Classification of Diagnostic, Therapeutic, and Surgical Procedures (2nd ed.). Ontario, Ottawa, Canada : Supply and Services, 1986.
21. World Health Organization International Classification of Diseases. Manual of the International Statistical Classification of Diseases, Injuries, and Cause of Death. 9th revision. Geneva, Switzerland : World Health Organization, 1977. PHS 2003 (15e, Ed).
22. Régie de l'Assurance Maladie du Québec. Rapport annuel de gestion 2005-2006. Governement of Quebec, 2006.
23. Tamblyn R, Lavoie G, Petrella L, Monette J. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995 48 : 999 1009.
24. Wilchesky M, Tamblyn RM, Huang A. Validation of diagnostic codes within medical services claims. J Clin Epidemiol 2004 57 : 131 141.
25. Tamblyn R, Reid T, Mayo N, et al. Using medical services claims to assess injuries in the elderly: sensitivity of diagnostic and procedure codes for injury ascertainment. J Clin Epidemiol 2000 53 : 183 194.
26. Monfared A, Rahme E, LeLorier J. Accuracy of ICD-9 diagnosis code "410" to identify episodes of hospitalizations for acute myocardial infarction in RAMQ. First Canadian Therapeutics Congress 2004. Halifax, Canada, 2004.
27. Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother 2006 40 : 1280 1288.
28. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care 2005 11 : 449 457.
29. Benner JS, Tierce JC, Ballantyne CM, et al. Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy. Pharmacoeconomics 2004 22 (Suppl. 3 S13 23.
30. Schultz JS, O'Donnell JC, McDonough KL, et al. Determinants of compliance with statin therapy and low-density lipoprotein cholesterol goal attainment in a managed care population. Am J Manag Care 2005 11 : 306 312.
31. Akobundu E, Ju J, Blatt L, Mullins CD. Cost-of-illness studies. A review of current methods. Pharmacoeconomics 2006 24 : 869 890.
32. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992 45 : 197 203.
33. Perreault S, Lamarre D, Blais L, et al. Persistence with treatment in newly treated middle-aged patients with essential hypertension. Ann Pharmacother 2005 39 : 1401 1408.
34. Mullahy J. Much ado about two: reconsidering retransformation and the two-part model in health economics. J Health Econ 1998 17 : 247 281.
35. Montez-Rath M, Christiansen CL, Ettner SL, et al. Performance of statistical models to predict mental health and substance abuse cost. BMC Med Res Methodol 2006 6 : 53.
36. Diehr P, Yanez D, Ash A, et al. Methods for analyzing health care utilization and costs. Annu Rev Public Health 1999 20 : 125 144.
37. Manning W, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ 2001 20 : 461 494.
38. Afifi A, Kotleman JB, Ettner SL, Cowan M. Methods for improving regression analysis for skewed continuous or counted responses. Annu Rev Public Health 2007 28 : 95 111.
39. Haukoos J, Lewis R Advanced statistics: bootstrapping confidence intervals for statistics with "difficult" distributions. Acad Emerg Med 2005 12 : 360 365.
40. Perreault S, Dragomir A, Blais L, et al. Impact of better adherence to statin agents in the primary prevention of coronary artery disease. Eur J Clin Pharmacol 2009 Jun 16 [Epub ahead of print S, Ellia L, Dragomir A, et al. Effect of statin adherence on cerebrovascular disease in primary prevention. Am J Med 2009 122 : 647 655.
41. Perreault S, Dragomir A, Blais L, et al. Impact of adherence to statins on chronic heart failure in primary prevention. Br J Clin Pharmacol 2008 66 : 706 716.
42. Sokol M, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and health care cost. Medical Care 2005 43 : 521 530.
43. Gibson T, Mark TL, Axelsen K, et al. Impact of statin copayments on adherence and medical care utilisation and expenditures. Am J Manag Care 2006 12 : SP11 9.
44. Salas M, Hofman A, Stricker BH. Confounding by indication: an example of variation in the use of epidemiology terminology. Am J Epidemiol 1999 149 : 981 983.
45. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005 353 : 487 497.
46. Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006 333 : 15 21.
47. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 2007 297 : 177 186.
48. Daskalopoulo SS, Delaney JAC, Filion KB, et al. Discontinuation of statin therapy following an acute myocardial infarction: a population-based study. Eur Heart J 2008 29 : 2083 2091.
49. Choo PW, Rand CS, Inui TS, et al. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care 1999 37 : 846 857.
50. Farahani P, Levine M, Gaebel K, et al. Exploring patient demographic and clinical characteristics associated with lipid-lowering pharmacotherapy use in primary care. Clin Invest Med 2007 30 : E63 9.
51. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006 15 : 565 574.